Report cover image

Global Gastric Mucosal Protective Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 191 Pages
SKU # APRC20278209

Description

Summary

According to APO Research, The global Gastric Mucosal Protective Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Gastric Mucosal Protective Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Gastric Mucosal Protective Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Gastric Mucosal Protective Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Gastric Mucosal Protective Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Gastric Mucosal Protective Drugs include Abbott, Takeda Pharmaceutical, Taiho Pharmaceutical, Sucralfate (Carafate), Pharmaking, Misoprostol (Cytotec), Eisai, Daewoong Pharmaceutical and Cadila Healthcare, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Gastric Mucosal Protective Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Gastric Mucosal Protective Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Gastric Mucosal Protective Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gastric Mucosal Protective Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Gastric Mucosal Protective Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Gastric Mucosal Protective Drugs sales, projected growth trends, production technology, application and end-user industry.

Gastric Mucosal Protective Drugs Segment by Company

Abbott
Takeda Pharmaceutical
Taiho Pharmaceutical
Sucralfate (Carafate)
Pharmaking
Misoprostol (Cytotec)
Eisai
Daewoong Pharmaceutical
Cadila Healthcare
Bismuth Subsalicylate (Pepto-Bismol)
AstraZeneca
Gastric Mucosal Protective Drugs Segment by Type

Oral Medicines
Injectable Medicines
Gastric Mucosal Protective Drugs Segment by Application

Child patients
Elderly patients
Youth patients
Infant patients
Gastric Mucosal Protective Drugs Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Mucosal Protective Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastric Mucosal Protective Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Mucosal Protective Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gastric Mucosal Protective Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastric Mucosal Protective Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gastric Mucosal Protective Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Gastric Mucosal Protective Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Gastric Mucosal Protective Drugs Market Size, 2020 VS 2024 VS 2031
1.3 Global Gastric Mucosal Protective Drugs Market Size Estimates and Forecasts (2020-2031)
1.4 Global Gastric Mucosal Protective Drugs Sales Estimates and Forecasts (2020-2031)
1.5 Global Gastric Mucosal Protective Drugs Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Gastric Mucosal Protective Drugs Market Dynamics
2.1 Gastric Mucosal Protective Drugs Industry Trends
2.2 Gastric Mucosal Protective Drugs Industry Drivers
2.3 Gastric Mucosal Protective Drugs Industry Opportunities and Challenges
2.4 Gastric Mucosal Protective Drugs Industry Restraints
3 Gastric Mucosal Protective Drugs Market by Manufacturers
3.1 Global Gastric Mucosal Protective Drugs Revenue by Manufacturers (2020-2025)
3.2 Global Gastric Mucosal Protective Drugs Sales by Manufacturers (2020-2025)
3.3 Global Gastric Mucosal Protective Drugs Average Sales Price by Manufacturers (2020-2025)
3.4 Global Gastric Mucosal Protective Drugs Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Gastric Mucosal Protective Drugs Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Gastric Mucosal Protective Drugs Manufacturers, Product Type & Application
3.7 Global Gastric Mucosal Protective Drugs Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Gastric Mucosal Protective Drugs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Gastric Mucosal Protective Drugs Players Market Share by Revenue in 2024
3.8.3 2024 Gastric Mucosal Protective Drugs Tier 1, Tier 2, and Tier 3
4 Gastric Mucosal Protective Drugs Market by Type
4.1 Gastric Mucosal Protective Drugs Type Introduction
4.1.1 Oral Medicines
4.1.2 Injectable Medicines
4.2 Global Gastric Mucosal Protective Drugs Sales by Type
4.2.1 Global Gastric Mucosal Protective Drugs Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Gastric Mucosal Protective Drugs Sales by Type (2020-2031)
4.2.3 Global Gastric Mucosal Protective Drugs Sales Market Share by Type (2020-2031)
4.3 Global Gastric Mucosal Protective Drugs Revenue by Type
4.3.1 Global Gastric Mucosal Protective Drugs Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Gastric Mucosal Protective Drugs Revenue by Type (2020-2031)
4.3.3 Global Gastric Mucosal Protective Drugs Revenue Market Share by Type (2020-2031)
5 Gastric Mucosal Protective Drugs Market by Application
5.1 Gastric Mucosal Protective Drugs Application Introduction
5.1.1 Child patients
5.1.2 Elderly patients
5.1.3 Youth patients
5.1.4 Infant patients
5.2 Global Gastric Mucosal Protective Drugs Sales by Application
5.2.1 Global Gastric Mucosal Protective Drugs Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Gastric Mucosal Protective Drugs Sales by Application (2020-2031)
5.2.3 Global Gastric Mucosal Protective Drugs Sales Market Share by Application (2020-2031)
5.3 Global Gastric Mucosal Protective Drugs Revenue by Application
5.3.1 Global Gastric Mucosal Protective Drugs Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Gastric Mucosal Protective Drugs Revenue by Application (2020-2031)
5.3.3 Global Gastric Mucosal Protective Drugs Revenue Market Share by Application (2020-2031)
6 Global Gastric Mucosal Protective Drugs Sales by Region
6.1 Global Gastric Mucosal Protective Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Gastric Mucosal Protective Drugs Sales by Region (2020-2031)
6.2.1 Global Gastric Mucosal Protective Drugs Sales by Region (2020-2025)
6.2.2 Global Gastric Mucosal Protective Drugs Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Gastric Mucosal Protective Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Gastric Mucosal Protective Drugs Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Gastric Mucosal Protective Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Gastric Mucosal Protective Drugs Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Gastric Mucosal Protective Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Gastric Mucosal Protective Drugs Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Gastric Mucosal Protective Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Gastric Mucosal Protective Drugs Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Gastric Mucosal Protective Drugs Revenue by Region
7.1 Global Gastric Mucosal Protective Drugs Revenue by Region
7.1.1 Global Gastric Mucosal Protective Drugs Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Gastric Mucosal Protective Drugs Revenue by Region (2020-2025)
7.1.3 Global Gastric Mucosal Protective Drugs Revenue by Region (2026-2031)
7.1.4 Global Gastric Mucosal Protective Drugs Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Gastric Mucosal Protective Drugs Revenue (2020-2031)
7.2.2 North America Gastric Mucosal Protective Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Gastric Mucosal Protective Drugs Revenue (2020-2031)
7.3.2 Europe Gastric Mucosal Protective Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Gastric Mucosal Protective Drugs Revenue (2020-2031)
7.4.2 Asia-Pacific Gastric Mucosal Protective Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Gastric Mucosal Protective Drugs Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Gastric Mucosal Protective Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Abbott
8.1.1 Abbott Comapny Information
8.1.2 Abbott Business Overview
8.1.3 Abbott Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Abbott Gastric Mucosal Protective Drugs Product Portfolio
8.1.5 Abbott Recent Developments
8.2 Takeda Pharmaceutical
8.2.1 Takeda Pharmaceutical Comapny Information
8.2.2 Takeda Pharmaceutical Business Overview
8.2.3 Takeda Pharmaceutical Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Takeda Pharmaceutical Gastric Mucosal Protective Drugs Product Portfolio
8.2.5 Takeda Pharmaceutical Recent Developments
8.3 Taiho Pharmaceutical
8.3.1 Taiho Pharmaceutical Comapny Information
8.3.2 Taiho Pharmaceutical Business Overview
8.3.3 Taiho Pharmaceutical Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Taiho Pharmaceutical Gastric Mucosal Protective Drugs Product Portfolio
8.3.5 Taiho Pharmaceutical Recent Developments
8.4 Sucralfate (Carafate)
8.4.1 Sucralfate (Carafate) Comapny Information
8.4.2 Sucralfate (Carafate) Business Overview
8.4.3 Sucralfate (Carafate) Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Sucralfate (Carafate) Gastric Mucosal Protective Drugs Product Portfolio
8.4.5 Sucralfate (Carafate) Recent Developments
8.5 Pharmaking
8.5.1 Pharmaking Comapny Information
8.5.2 Pharmaking Business Overview
8.5.3 Pharmaking Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Pharmaking Gastric Mucosal Protective Drugs Product Portfolio
8.5.5 Pharmaking Recent Developments
8.6 Misoprostol (Cytotec)
8.6.1 Misoprostol (Cytotec) Comapny Information
8.6.2 Misoprostol (Cytotec) Business Overview
8.6.3 Misoprostol (Cytotec) Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Misoprostol (Cytotec) Gastric Mucosal Protective Drugs Product Portfolio
8.6.5 Misoprostol (Cytotec) Recent Developments
8.7 Eisai
8.7.1 Eisai Comapny Information
8.7.2 Eisai Business Overview
8.7.3 Eisai Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Eisai Gastric Mucosal Protective Drugs Product Portfolio
8.7.5 Eisai Recent Developments
8.8 Daewoong Pharmaceutical
8.8.1 Daewoong Pharmaceutical Comapny Information
8.8.2 Daewoong Pharmaceutical Business Overview
8.8.3 Daewoong Pharmaceutical Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Daewoong Pharmaceutical Gastric Mucosal Protective Drugs Product Portfolio
8.8.5 Daewoong Pharmaceutical Recent Developments
8.9 Cadila Healthcare
8.9.1 Cadila Healthcare Comapny Information
8.9.2 Cadila Healthcare Business Overview
8.9.3 Cadila Healthcare Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Cadila Healthcare Gastric Mucosal Protective Drugs Product Portfolio
8.9.5 Cadila Healthcare Recent Developments
8.10 Bismuth Subsalicylate (Pepto-Bismol)
8.10.1 Bismuth Subsalicylate (Pepto-Bismol) Comapny Information
8.10.2 Bismuth Subsalicylate (Pepto-Bismol) Business Overview
8.10.3 Bismuth Subsalicylate (Pepto-Bismol) Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Bismuth Subsalicylate (Pepto-Bismol) Gastric Mucosal Protective Drugs Product Portfolio
8.10.5 Bismuth Subsalicylate (Pepto-Bismol) Recent Developments
8.11 AstraZeneca
8.11.1 AstraZeneca Comapny Information
8.11.2 AstraZeneca Business Overview
8.11.3 AstraZeneca Gastric Mucosal Protective Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 AstraZeneca Gastric Mucosal Protective Drugs Product Portfolio
8.11.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Gastric Mucosal Protective Drugs Value Chain Analysis
9.1.1 Gastric Mucosal Protective Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Gastric Mucosal Protective Drugs Production Mode & Process
9.2 Gastric Mucosal Protective Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Gastric Mucosal Protective Drugs Distributors
9.2.3 Gastric Mucosal Protective Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.